Abstract A pharmaceutical worker developed asthma when exposed to hydralazine, an antihypertensive drug. The diagnosis of occupational asthma was supported by specific inhalation challenges, which produced a late asthmatic reaction and an increase in bronchial responsiveness. No evidence of an IgE or an IgG dependent mechanism could be found.
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Accepted 20 June 1990 Case report A 35 year old man had worked for four years as an operator at a pharmaceutical plant. Two years after beginning this work he noticed sneezing, dyspnoea, and wheezing on exposure to psyllium. Occupational asthma due to psyllium was excluded on the basis of negative results from an inhalation challenge test, in which the man was asked to tip psyllium from one tray to another in a challenge room.'2 He showed no immediate skin reactivity to psyllium and the levels of specific IgE antibodies were normal (in contrast to occupational asthma due to psyllium in our experience3 4). The subject also reported having symptoms of seasonal rhinitis since he was 18, which had become perennial in the preceding two years. The finding of bronchial hyperresponsiveness with a provocation concentration of methacholine causing a 20% fall in FEV1 (PC20) of 15 mg/ml' led to a diagnosis of asthma in 1985.
The subject moved to another pharmaceutical company in 1985, where he also worked as an operator and where his exposure to hydralazine began, four years before his referral in 1989. In the preceding year he had noticed symptoms of sneezing, dyspnoea, and wheezing during the second day that hydralazine was being prepared. The symptoms appeared progressively and persisted for the four or five days when hydralazine was being made. He improved once the preparation of hydralazine had ended. Hydralazine was prepared every one to two months for four to five days. Skinprick tests with 15 common inhalant allergens and hydralazine diluted in phosphate buffered saline in concentrations of 01 and 1 mg/ml gave negative results. The total serum IgE level was 96 IU/l (normal). Tests for serum IgE antibodies to Dermatophagoides farinae, cat danders, and ragweed and grass pollens gave negative results.
Specific inhalation challenges were performed after four days away from work. The results are illustrated in the figure. On the first day the patient was exposed to lactose for 15 minutes with a new aerosolisation device,6 which keeps the concentration of particles under 10 mg/m3 (threshold limit value-short term exposure level or TLV-STEL). Baseline FEVy was 85% predicted.7 FEV, did not fluctuate by more then 10% during the day. The PC20 for methacholine was 1-7 mg/ml, confirming the mild bronchial hyperresponsiveness that had been seen a few years before. On the second day the patient was exposed to hydralazine for seven minutes with the same apparatus: no fluctuations in FEVy of more than 10% were noticed during exposure or in the next few hours (a maximum increase in FEV, of 5% was observed). On the third day the subject was exposed to hydralazine for progressively increasing periods totalling 30 minutes. He experienced a late asthmatic reaction with cough and shortness of breath. A maximal fall in FEVy of 35-4% was recorded 270 minutes after exposure. Bronchoconstriction persisted for two hours. A bronchodilator was administered, with complete functional recovery. FEVy remained below 90% of the baseline value for three days after the late reaction, but had returned to baseline by eight days after the inhalation test, at which time the PC20 was still low at 0 5 mg/ml.6 PC20 was still reduced at 11 days (0-44 mg/ml) but had returned to baseline at 22 days (1 3 mg/ml).
Tests for IgE and IgG antibodies to hydralazine were performed by the radioallergosorbent test and the enzyme linked immunosorbent assay respectively by methods previously described.8 The results were negative. The character of the author and his enormous grasp of respiratory medicine emerge clearly from the text of this second edition of his book, which was completed just a few weeks before his tragic death. The book is effectively a highly condensed comprehensive textbook of respiratory disease. The reader is spared no detail of the underlying science wherever this is relevant and the book acts as a convenient outline of the current state of knowledge in the subject as a whole. The book is highly suitable for the very best medical students and for those junior doctors who find themselves rotating through a respiratory medicine unit. It is a fund of information that even Blackwell, 1990. ISBN 0-632-02848-3. This book, which is a summary of a meeting held in 1988, attempts to address some basic and applied aspects of eosinophil biology and in this it succeeds. What is more difficult is to find a role for this publication. It is a mixture oftwo types ofchapter. Firstly, there are some excellent reviews, in particular the chapters by Capron, Kay, and Barnes, which review the immunoglobulin receptors, chemotactic factors, and pharmacology of the eosinophil and are very useful reference sources. The other 15 chapters review the research interest of the groups presenting the data, some ofwhich represent up to date summaries of the work. Six of these chapters, however, do not contain any references more recent than 1988 and therefore fail to be useful for readers looking to this book for up to date information in those areas. Thus, although this book contains good reviews and some up to date research chapters, it is difficult to be certain of the audience it is aimed at as it does not fall into the role of textbook for the general library, or provide comprehensive, up to the minute research papers for the laboratory dedicated to studying the eosinophil or bronchial hyperreactivity.-RWF
